


MAR 06 2002

RECEIVED

TECH CENTER 1600/2900



In Patent Application of

Kenneth C. Cundy. et al.

Application No.: 09/972,402

Filed: October 5, 2001

For: Compounds for Sustained Release of
Orally Delivered Drugs

Group Art Unit: 1619

Examiner: Unassigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of IDS as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of IDS as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,
BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300
Date:

By:

Gerald F. Swiss

Registration No. 30,113



Patent Application no. 09/972,402
Attorney's Docket No. 033053-02

RECEIVED
MAR 06 2002
TECH CENTER 1600/2900
3/15/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Kenneth C. Cundy. et al.) Group Art Unit: 1619
)
Application No.: 09/972,402) Examiner: Unassigned
)
Filed: October 5, 2001)
)
For: Compounds for Sustained Release of)
Orally Delivered Drugs)
)
)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed:

Articles:

Kagedahl, et al., "Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity", *Pharmaceutical Research*, Vol. 14, No. 2, pp. 176-180 (1997).

Russell-Jones, et al., "Vitamin B12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin", *Bioconjugate Chemistry*, Vol. 6, pp. 459-465, (1995).

Shah, et al., "Transcellular Delivery of an Insulin-transferrin conjugate in Enterocyte-like Caco-2 cells", *J. Pharm. Sciences*, Vol. 85, No. 12, pp. 1306-1311 (1996)

Swaan, et al., Preface - Advanced Drug Delivery Reviews, Vol. 20, pp. 1-3, (1996)

Swaan, et al., "Use of intestinal and hepatic bile acid transporters for drug delivery", *Advanced Drug Delivery Reviews*, Vol. 20, pp. 59-82, (1996)


The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication received from the US/RO acting as the search authority for the equivalent PCT application. Applicants submit that this constitutes a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Gerald F. Swiss
Registration No. 30,113

Burns, Doane, Swecker & Mathis
P.O. Box 1404
Arlington, VA 22313
Firm Phone: (650) 622-2300

Date: